Generic entry of aromatase inhibitors and pharmaceutical access: Initiation of hormonal therapy, timeliness of initiation, and drug choice

This publication has 21 references indexed in Scilit:

• The Change From Brand-Name to Generic Aromatase Inhibitors and Hormone Therapy Adherence for Early-Stage Breast Cancer
  JNCI: Journal of the National Cancer Institute, 2014
• Changes in Physician Antipsychotic Prescribing Preferences, 2002–2007
  Psychiatric Services, 2014
• Infused Chemotherapy Use in the Elderly After Patent Expiration
  Journal of Oncology Practice, 2012
• Use of Surveillance, Epidemiology, and End Results-Medicare Data to Conduct Case-Control Studies of Cancer Among the US Elderly
  American Journal of Epidemiology, 2011
• American Society of Clinical Oncology Clinical Practice Guideline Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
  Journal of Oncology Practice, 2010
• Patients’ Perceptions Of Generic Medications
  Health Affairs, 2009
• Is There a Relationship Between Patient Beliefs or Communication About Generic Drugs and Medication Utilization?
  Medical Care, 2009
• Physician Awareness of Drug Cost: A Systematic Review
  PLOS Medicine, 2007
• Access To Cancer Drugs In Medicare Part D: Formulary Placement And Beneficiary Cost Sharing In 2006
  Health Affairs, 2006
• American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004
  Journal of Clinical Oncology, 2005